lobbying_activities: 1921771

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1921771	a3134804-984b-404c-aad1-0f99f78b5bc0	Q4	FOLEY & LARDNER LLP	15042	PAR PHARMACEUTICAL	2016	fourth_quarter	PHA	FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market; Issues relating to the Comprehensive Addiction and Recovery Act of 2016.	HOUSE OF REPRESENTATIVES,SENATE			0	0	2017-01-19T11:32:40-05:00